Merck KGaA MGKAY and Pfizer PFE today announced that the
European Medicines Agency (EMA)'s Committee for Orphan Medicinal
Products (COMP) has issued a positive opinion for Orphan Drug
designation (ODD) for avelumab*, an investigational fully human
anti-PD-L1 IgG1 monoclonal antibody, pending an official decision by the
European Commission (EC), expected in December. The COMP positive
opinion is for the cancer immunotherapy avelumab, for the treatment of
Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer.1,2
Each year, there are approximately 2,500 new cases of MCC diagnosed in
the European Union (EU).3 There is currently no therapy
approved specifically for the treatment of metastatic MCC.4
"While significant therapeutic advances have
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in